Cagrilintide & CagriSema: Trial Evidence, FDA Status & What's Actually Legal

Common contexts

• Clinics may reference this peptide within broader wellness or longevity pathways.
• Use this directory page to compare profile transparency and consultation options.

Safety information

• This directory is informational and does not provide medical advice.
• Always discuss suitability and risk profile directly with a licensed clinician.

Clear intro

Cagrilintide is what the next generation of weight-management medicine looks like mid-transition: spectacular trial data, an FDA decision pending, and a grey market that has already decided not to wait. The gap between those two realities is exactly what anyone searching 'cagrilintide' needs explained.

Who this is for

This page is for people following the CagriSema results who want to know what is actually available today, and for anyone being offered 'cagrilintide' online who deserves to know what that product really is.

What to ask before choosing a clinic

• CagriSema is not yet approved — if you are offering cagrilintide today, where does it come from?
• Would semaglutide or tirzepatide — approved, with strong evidence — meet my goals now?
• When CagriSema is approved, will you offer it through standard prescribing channels?

Pricing and red flags

Compare only against approved options. Any money spent on pre-approval 'cagrilintide' buys an unverifiable product with no regulatory oversight — the number on the invoice is the least of the problems.

• Any sale of 'cagrilintide' or 'CagriSema' before regulatory approval — there is no legitimate supply chain yet.
• Quoting REDEFINE-1 percentages as if they apply to grey-market vials of a single component.
• Framing the FDA filing as approval — a filing is a request, not a decision.

What is Cagrilintide?

Cagrilintide is a synthetic analogue of amylin — a pancreatic hormone co-secreted with insulin that signals satiety through pathways distinct from GLP-1. Novo Nordisk developed it as a once-weekly injection and, most importantly, as the partner molecule in CagriSema: cagrilintide 2.4 mg plus semaglutide 2.4 mg in a single weekly dose, the first combination of an amylin analogue and a GLP-1 medicine to complete Phase 3 trials. In the REDEFINE-1 trial (3,417 adults with obesity or overweight, 68 weeks), the combination outperformed either component alone. Novo Nordisk submitted its FDA application in December 2025; as of mid-2026 no regulator anywhere has approved cagrilintide in any form.

How it works

Amylin slows gastric emptying and acts on hindbrain satiety circuits — appetite suppression through a second, complementary hormone system. The logic of CagriSema is stacking that mechanism on top of GLP-1 receptor agonism, and the trial numbers suggest the stack works: in the December 2024 REDEFINE-1 readout, the combination produced 20.4% average weight loss versus 14.9% for semaglutide alone and 11.5% for cagrilintide alone (placebo 3%), with later analyses reporting up to 22.7% depending on the statistical estimand. What the mechanism does not do is make grey-market 'cagrilintide' a sensible purchase — the trial product is a precisely dosed pharmaceutical combination, not a vial from an unregulated vendor.

Cost overview

There is no legitimate price because there is no approved product. Grey-market vials are unverifiable in identity, dose, and purity. Once CagriSema is approved, pricing will be set as a branded pharmaceutical — until then, the only evidence-based spending is on approved medicines. See the peptide therapy cost guide.

What to expect from clinics

• A credible provider should state plainly that neither cagrilintide nor CagriSema is approved anywhere yet.
• Expect approved alternatives (semaglutide, tirzepatide) to be offered first — they are prescribable today with strong evidence.
• Any clinic offering 'cagrilintide' before approval is sourcing from unregulated suppliers, whatever the paperwork looks like.

Safety considerations

In trials, CagriSema's tolerability profile was broadly consistent with the GLP-1 class — predominantly gastrointestinal side effects. But that safety data belongs to the pharmaceutical-grade combination under clinical supervision, not to grey-market vials of unknown identity and dose. Before approval, there is no product outside a trial whose contents can be trusted. This page does not recommend cagrilintide and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.